Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
May 4, 2020 (Issue: 1597)
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT –
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant"), for
acute treatment of migraine with or...more
- Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:35.
- Erenumab (Aimovig) for migraine prevention. Med Lett Drugs Ther 2018; 60:101.
- Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention. Med Lett Drugs Ther 2018; 60:177.
- Drugs for migraine. Med Lett Drugs Ther 2017; 59:27.
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59:1.
- ME Bigal et al. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53:1230.
- R Croop et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019; 394:737.
- RB Lipton et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019; 381:142.
- R Marcus et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, dose-ranging trial. Cephalgia 2014; 34:114.
- K Mullin et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020 Jan 13 (epub).
- GD Berman et al. Oral rimegepant 75 mg is well-tolerated when used concomitantly with injectable anti-CGRP monoclonal antibodies: results from a multicenter, long-term, open-label safety study. Presented at the American Academy of Neurology Conference, Philadelphia, PA, April 26, 2020. Abstract 008.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- DW Dodick et al. Ubrogepant achieves early pain relief for acute treatment of migraine. 60th Annual Scientific Meeting of the American Headache Society; San Francisco, CA, June 28-July 1, 2018. Poster P103.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
Article code: 1597d
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
